Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activation of type II NADH dehydrogenase by quinolinequinones mediates antitubercular cell death
Adam Heikal, Kiel Hards, Chen‐Yi Cheung, et al.
Journal of Antimicrobial Chemotherapy (2016) Vol. 71, Iss. 10, pp. 2840-2847
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development
Tiago Beites, Kathryn O’Brien, Divya Tiwari, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 104
Potential of Mycobacterium tuberculosis Type II NADH-Dehydrogenase in Antitubercular Drug Discovery
Pallavi Saha, Mahesh Kumar, Deepak K. Sharma
ACS Infectious Diseases (2025)
Closed Access
Targeting bacterial energetics to produce new antimicrobials
Kiel Hards, Gregory M. Cook
Drug Resistance Updates (2017) Vol. 36, pp. 1-12
Closed Access | Times Cited: 84
Dual inhibition of the terminal oxidases eradicates antibiotic‐tolerant Mycobacterium tuberculosis
Bei Shi Lee, Kiel Hards, Curtis A. Engelhart, et al.
EMBO Molecular Medicine (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 65
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering
Brendon M. Lee, Liam K. Harold, Deepak V. Almeida, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 2, pp. e1008287-e1008287
Open Access | Times Cited: 64
Clofazimine: A useful antibiotic for drug-resistant tuberculosis
Reza Mirnejad, Arezoo Asadi, Saeed Khoshnood, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 105, pp. 1353-1359
Closed Access | Times Cited: 63
2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization
Dinakaran Murugesan, Peter C. Ray, Tracy Bayliss, et al.
ACS Infectious Diseases (2018) Vol. 4, Iss. 6, pp. 954-969
Open Access | Times Cited: 58
Cytochrome bd in Mycobacterium tuberculosis: A respiratory chain protein involved in the defense against antibacterials
Ludovica Mascolo, Dirk Bald
Progress in Biophysics and Molecular Biology (2019) Vol. 152, pp. 55-63
Open Access | Times Cited: 46
Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis
Caroline S. Foo, Kévin Pethe, Andréanne Lupien
Applied Sciences (2020) Vol. 10, Iss. 7, pp. 2339-2339
Open Access | Times Cited: 43
Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis
Erik J. Hasenoehrl, Thomas J. Wiggins, Michael Berney
Frontiers in Cellular and Infection Microbiology (2021) Vol. 10
Open Access | Times Cited: 36
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis
Nicole C. Ammerman, Rosemary V. Swanson, Elaine M. Bautista, et al.
Antimicrobial Agents and Chemotherapy (2018) Vol. 62, Iss. 7
Open Access | Times Cited: 42
A review on enzyme complexes of electron transport chain from Mycobacterium tuberculosis as promising drug targets
Pragya Anand, Yusuf Akhter
International Journal of Biological Macromolecules (2022) Vol. 212, pp. 474-494
Closed Access | Times Cited: 19
Naphthoquinone Derivatives as Scaffold to Develop New Drugs for Tuberculosis Treatment
Priscila Cristina Bartolomeu Halicki, Laís A. Ferreira, Kelly C. G. de Moura, et al.
Frontiers in Microbiology (2018) Vol. 9
Open Access | Times Cited: 32
In situ solid-state fabrication of Z-Scheme BiVO4/g-C3N4 heterojunction photocatalyst with highly efficient-light visible activity and their antibacterial properties against bacterial pathogens
Azam Khan, Mohammad Altaf, Mohammad Shahid, et al.
Journal of Molecular Structure (2023) Vol. 1300, pp. 137222-137222
Closed Access | Times Cited: 9
Myricetin Acts as an Inhibitor of Type II NADH Dehydrogenase from Staphylococcus aureus
Jiale Zhou, H.-Y. Chen, Jian Xu, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2354-2354
Open Access | Times Cited: 2
Type-II NADH Dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery
Satheeshkumar Sellamuthu, Meenakshi Singh, Ashok Kumar, et al.
Expert Opinion on Therapeutic Targets (2017) Vol. 21, Iss. 6, pp. 559-570
Closed Access | Times Cited: 31
Two for the price of one: Attacking the energetic-metabolic hub of mycobacteria to produce new chemotherapeutic agents
Kiel Hards, Cara Adolph, Liam K. Harold, et al.
Progress in Biophysics and Molecular Biology (2019) Vol. 152, pp. 35-44
Closed Access | Times Cited: 27
The synthesis and evaluation of quinolinequinones as anti-mycobacterial agents
Kristiana T. Santoso, Ayana Menorca, Chen‐Yi Cheung, et al.
Bioorganic & Medicinal Chemistry (2019) Vol. 27, Iss. 16, pp. 3532-3545
Closed Access | Times Cited: 25
Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis
Milan Urban, Veronika Šlachtová, Lucie Brulíková
European Journal of Medicinal Chemistry (2020) Vol. 212, pp. 113139-113139
Closed Access | Times Cited: 25
Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors
Maria Giulia Nizi, Jenny Desantis, Yoshio Nakatani, et al.
European Journal of Medicinal Chemistry (2020) Vol. 201, pp. 112420-112420
Closed Access | Times Cited: 23
Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against Mycobacterium tuberculosis
Kevin Timothy Fridianto, Ming Li, Kiel Hards, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 21, pp. 15991-16007
Open Access | Times Cited: 14
Molecular diagnostics and potential therapeutic options for mycobacterium tuberculosis: Where we stand
Zafran Khan, Daniya Ualiyeva, Khalid Jamal, et al.
Medicine in Omics (2023) Vol. 8, pp. 100022-100022
Open Access | Times Cited: 5
Multiplexed transcriptional repression identifies a network of bactericidal interactions between mycobacterial respiratory complexes
Matthew B. McNeil, Heath W. K. Ryburn, Justin F. Tirados, et al.
iScience (2021) Vol. 25, Iss. 1, pp. 103573-103573
Open Access | Times Cited: 13
Inhibition of Escherichia coli and Bacillus subtilis FtsZ Polymerization and Bacillus subtilis Growth by Dihydroxynaphtyl Aryl Ketones
Gissela Araya, Julio Benites, Juan Sebastián Reyes, et al.
Frontiers in Microbiology (2019) Vol. 10
Open Access | Times Cited: 12
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid
Sarah Kim, Arnold Louie, George L. Drusano, et al.
International Journal of Antimicrobial Agents (2021) Vol. 59, Iss. 2, pp. 106509-106509
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top